Roth Capital Predicts Nuvectis Pharma Q1 Earnings

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Stock analysts at Roth Capital issued their Q1 2025 EPS estimates for shares of Nuvectis Pharma in a report released on Tuesday, November 5th. Roth Capital analyst J. Aschoff anticipates that the company will earn ($0.23) per share for the quarter. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.05) per share. Roth Capital also issued estimates for Nuvectis Pharma’s Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.23) EPS and FY2028 earnings at $3.61 EPS.

Nuvectis Pharma (NASDAQ:NVCT) last announced its earnings results on Tuesday, November 5th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. During the same quarter in the previous year, the firm earned ($0.37) earnings per share.

Separately, HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of Nuvectis Pharma in a research note on Tuesday, August 6th.

Nuvectis Pharma Trading Up 2.3 %

Nuvectis Pharma stock opened at $8.34 on Wednesday. The stock has a 50 day moving average of $6.84 and a two-hundred day moving average of $6.69. Nuvectis Pharma has a twelve month low of $5.85 and a twelve month high of $12.10. The stock has a market capitalization of $155.54 million, a price-to-earnings ratio of -6.47 and a beta of 0.41.

Institutional Trading of Nuvectis Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Nuvectis Pharma by 1.5% in the first quarter. Vanguard Group Inc. now owns 298,800 shares of the company’s stock valued at $2,450,000 after purchasing an additional 4,517 shares during the period. Baldwin Brothers LLC MA raised its stake in shares of Nuvectis Pharma by 9.4% during the 2nd quarter. Baldwin Brothers LLC MA now owns 168,630 shares of the company’s stock worth $1,067,000 after buying an additional 14,500 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Nuvectis Pharma by 20.7% in the 2nd quarter. Renaissance Technologies LLC now owns 74,500 shares of the company’s stock valued at $472,000 after buying an additional 12,800 shares during the period. Iridian Asset Management LLC CT acquired a new stake in shares of Nuvectis Pharma in the 3rd quarter valued at approximately $348,000. Finally, GSA Capital Partners LLP boosted its stake in shares of Nuvectis Pharma by 3.7% in the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock valued at $315,000 after buying an additional 1,790 shares in the last quarter. Hedge funds and other institutional investors own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.